Mina Ding
Gwangju, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Discovery of TCP-(MP)-caffeic acid analogs as a new class of agents for treatment of osteoclastic bone loss.
Journal: Bioorganic chemistry
Published: February 28, 2024
Discovery of PMSA Derivative 11 as a Novel Lead Compound for Therapeutic Treatment of Osteoporosis In Vitro and In Vivo.
Journal: Journal of medicinal chemistry
Published: May 08, 2023
Synthesis and evaluation of 2-NMPA derivatives as potential agents for prevention of osteoporosis in vitro and in vivo.
Journal: European journal of medicinal chemistry
Published: March 30, 2023
(S)-2-(Cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide Attenuates RANKL-Induced Osteoclast Differentiation by Inhibiting NF-κB Nuclear Translocation.
Journal: International journal of molecular sciences
Published: January 20, 2023
Crucial Role of Lysine-Specific Histone Demethylase 1 in RANKL-Mediated Osteoclast Differentiation.
Journal: International journal of molecular sciences
Published: December 19, 2022
Identification of Novel Genes for Cell Fusion during Osteoclast Formation.
Journal: International journal of molecular sciences
Published: April 18, 2022
2-NPPA Mitigates Osteoclastogenesis via Reducing TRAF6-Mediated c-fos Expression.
Journal: Frontiers in pharmacology
Published: August 26, 2020
PMSA prevents osteoclastogenesis and estrogen-dependent bone loss in mice.
Journal: Bone
Published: July 27, 2020
N-[2-(4-benzoyl-1-piperazinyl)phenyl]-2-(4-chlorophenoxy) acetamide is a novel inhibitor of resorptive bone loss in mice.
Journal: Journal of cellular and molecular medicine
Published: May 25, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026